You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
重藥控股(000950.SZ):化醫集團與最終受讓方簽署的產權交易合同已生效
格隆匯 11-07 21:24

格隆匯11月7日丨重藥控股(000950.SZ)公佈,2019年10月23日,重藥控股披露,重慶聯合產權交易所確定此次交易的最終受讓方為中國通用及中國醫藥組成的聯合體。此次交易的掛牌底價為人民幣41億元。化醫集團將按照重慶聯合產權交易所的相關流程與中國通用及中國醫藥協商簽署《產權交易合同》。

2019年10月31日,重藥控股披露,化醫集團已就公開掛牌轉讓健康產業公司49%股權項目於2019年10月29日與最終受讓方中國通用及其控股子公司中國醫藥簽署《產權交易合同》,交易價格為人民幣41億元整。《產權交易合同》自中國醫藥股東大會批准之日生效。

2019年11月7日,中國醫藥召開股東大會審議通過了此次交易,此次交易的《產權交易合同》自2019年11月7日生效,化醫集團與中國醫藥及中國通用將按照《產權交易合同》的約定辦理健康產業公司股權過户事宜。

健康產業公司持有公司38.47%股份,為公司的控股股東;化醫集團持有健康產業公司100%股權,為健康產業公司的控股股東。此次股權轉讓實施完畢之後,化醫集團將持有健康產業公司51%股權,中國通用及中國醫藥將合計持有健康產業公司49%股權,其中:中國通用持有健康產業公司22%股權、中國醫藥持有健康產業公司27%股權。重藥控股的控股股東仍為健康產業公司,重藥控股的實際控制人仍為重慶市國有資產監督管理委員會,重藥控股的控制權不會發生變更。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account